Background: The activity of transient receptor potential vanilloid subtype-1 (TRPV1) receptors, key nociceptive transducers in dorsal root ganglion sensory neurons, is enhanced by protein kinase C (PKC) activation. The intravenous anesthetic propofol has been shown to activate PKC. Our objectives were to examine whether propofol modulates TRPV1 function in dorsal root ganglion neurons via activation of PKC. Methods: Lumbar dorsal root ganglion neurons from wildtype and PKC-null mice were isolated and cultured for 24 h. Intracellular free Ca 2ϩ concentration was measured in neurons by using fura-2 acetoxymethyl ester. The duration of pain-associated behaviors was also assessed. Phosphorylation of PKC and TRPV1 and the cellular translocation of PKC from cytosol to membrane compartments were assessed by immunoblot analysis. Results: In wild-type neurons, repeated stimulation with capsaicin (100 nM) progressively decreased the transient rise in intracellular free Ca 2ϩ concentration. After desensitization, exposure to propofol rescued the Ca 2ϩ response. The resensitizing effect of propofol was absent in neurons obtained from PKC-null mice. Moreover, the capsaicin-induced desensitization of TRPV1 was markedly attenuated in the presence of propofol in neurons from wild-type mice but not in neurons from PKC-null mice.
longed the duration of agonist-induced pain associated behaviors in wild-type mice. In addition, propofol increased phosphorylation of PKC as well as TRPV1 and stimulated translocation of PKC from cytosolic to membrane fraction. Discussion: Our results indicate that propofol modulates TRPV1 sensitivity to capsaicin and that this most likely occurs through a PKC-mediated phosphorylation of TRPV1.
T RANSIENT receptor potential vanilloid subtype-1 (TRPV1) receptors are expressed mainly by peripheral sensory neurons and serve as detectors of pain-producing chemical and thermal stimuli. 1, 2 They act as nonselective cation channels with high Ca 2ϩ permeability and can be distinguished from other sensory transducers by their sensitivity to capsaicin. 3 A variety of chemical agents acutely sensitize TRPV1 receptors to thermal stimuli and result in the sensation of pain, [4] [5] [6] [7] [8] whereas repetitive stimulation of the receptor causes desensitization, which plays an important role in blocking pain transmission. 5, 6, 9 The cellular mechanisms mediating sensitization, desensitization, and resensitization of the receptor are thought to involve changes in receptor phosphorylation. 9 -11 Specifically, activation of PKC seems to mediate sensitization of TRPV1 to agonist stimulation via phosphorylation of TRPV1 at serine 800 (S800). 5, 12, 13 Propofol is one of the most commonly used intravenous anesthetics for the induction and maintenance of general anesthesia and sedation. Apart from its anesthetic properties, propofol has several nonanesthetic effects, one of which is the modulation of pain. A recent study indicated that propofol increases intracellular free Ca 2ϩ concentration ([Ca 2ϩ ] i ) in transfected human embryonic kidney 293 cells via a transient receptor potential ankrin subtype-1 (TRPA1)-dependent pathway. 14 Moreover , recent evidence has suggested that functional regulation of the transient receptor potential family of receptors may be mediated by cross-talk between family members, particularly TRPV1 and TRPA1. 15, 16 In addition, our laboratory has previously shown that propofol activates PKC in isolated cardiomyocytes 17 as well as recombinant PKC, 18 suggesting that propofol may activate PKC in dorsal root ganglion (DRG) neurons and potentially modulate TRPV1 sensitivity to agonist-stimulation.
In the current study, we tested the hypothesis that propofol not only restores the sensitivity of desensitized TRPV1 receptors, but also attenuates agonist-induced desensitization of TRPV1 in DRG neurons via a PKC-dependent pathway. The major findings are that pretreatment with propofol or the PKC activator peptide (RACK) resensitizes TRPV1 receptors. Moreover, the PKC selective inhibitor peptide (V1-2) prevents the propofol-induced rescue of TRPV1 sensitivity, and propofol fails to exert any effect on restoration of TRPV1 in DRG neurons isolated from PKCnull mice. Propofol attenuates agonist-induced desensitization of TRPV1 in DRG neurons isolated from wild-type (WT) mice but not in neurons isolated from PKC-null mice. Moreover, propofol prolongs the duration of agonistinduced pain-associated behaviors in mice. Propofol also increases the membrane association of PKC as well as the phosphorylation of PKC at S729. Finally, propofol increases the PKC-dependent phosphorylation of TRPV1 at S800. Our current findings indicate that propofol can resensitize TRPV1 receptors and attenuate agonist-induced desensitization of TRPV1 via a PKC-dependent phosphorylation of TRPV1.
Materials and Methods

Animals
Twelve-week-old male C57BL/6 PKC-null mice (PKCϪ/Ϫ) and age/sex-matched PKC WT mice (PKCϩ/ϩ) were used. PKCϩ/Ϫ mice breeding pairs were kindly provided by Robert O. Messing, M.D. (Ernest Gallo Clinic and Research Center, University of California at San Francisco, San Francisco, California). All animals were housed at an animal care facility at Kent State University (Kent, Ohio) that is accredited by the American Association for Accreditation of Laboratory Animal Care.
DRG Cell Isolation and Culture
DRG neurons from WT and PKC-null adult mice (30 -40 g) were used in this study. The ganglia were dissected from the lumbar (L1-L6) segments of the spinal cord and incubated with collagenase (type IV, 0.15%) at 37°C for 50 min and dissociated by gentle trituration. Neurons were cultured on coverglasses precoated with poly-D-lysine and laminin at 37°C in Ham's F-12 medium/Dulbecco's modified Eagle's medium (50/50) supplemented with 10% fetal bovine serum and antibiotics in a humidified atmosphere of 5% CO 2 and 95% air. Proliferation of fibroblasts and Schwann cells was prevented by including cytosine arabinoside (5-10 M) in the medium. Cells began to develop neurites within ϳ24 h, and studies were performed within 24 h from the time of isolation.
Intracellular Ca 2؉ Measurements
DRG neurons were incubated at room temperature (23°C) for 15 min with fura-2 acetoxymethyl ester (2 M) in HEPES-buffered saline containing the following: 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgCl 2 , 1.25 mM CaCl 2 , 11.0 mM dextrose, 5 mM pyruvate, and 25 mM HEPES, pH 7.35. Coverslips containing the fura-2 acetoxymethyl ester-loaded DRG neurons were placed in a temperature-regulated (30°C) chamber (Warner Instruments, Hamden, CT) mounted on the stage of an Olympus IX-81 inverted fluorescence microscope (Olympus America, Lake Success, NY). The cells were superfused continuously with HEPES-buffered saline at a flow rate of 2 ml/min. Drugs were delivered by switching from control buffer to drug-containing buffer for 20 s unless noted otherwise. [Ca 2ϩ ] i measurements were simultaneously performed on multiple individual DRG neurons using a fluorescence imaging system (Easy Ratio Pro; Photon Technology International, Lawrenceville, NJ) equipped with a multi wavelength spectrofluorometer (DeltaRAM X) and a QuantEM 512SC electron multiplying charge-coupled device camera (Photometrics, Tuscan, AZ). Images and photometric data were acquired by alternating excitation wavelengths between 340 and 380 nm (20 Hz) and monitoring an emission wavelength of 510 nm. Because calibration procedures rely on a number of assumptions, the ratio of the light intensities at the two wavelengths was used to measure qualitative changes in [Ca 2ϩ ] i . Just before data acquisition, background fluorescence was measured and automatically subtracted from the subsequent experimental measurement by using Easy Ratio Pro.
Behavioral Experiments
In vivo assessment of pain-associated behaviors in WT mice were assessed as described by Matta et al. 14 with slight modifications. Capsaicin and/or propofol were applied to the nasal epithelium of WT mice via a cotton applicator, and the duration (in seconds) of pain-associated behaviors (nose wiping in and out of sawdust bedding) was assessed and measured by a blinded observer.
Subcellular Fractionation of DRG Neurons
Fractionation of mouse DRG neurons was performed as previously reported for cardiomyocytes with slight modifications. 17 After treatment with propofol, DRG neurons were pelleted by centrifugation (45 s at 800g) and washed with ice cold HEPES-buffered saline. Neurons were resuspended in lysis buffer (4 mM MgATP, 100 mM KCl, 10 mM imidazole, 2 mM EGTA, 1 mM MgCl 2 , 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 10 mM benzamidine, and 0.01 mM leupeptin) containing 20% glycerol and 0.05% Triton X-100. Cell permeabilization and membrane solubilization were facilitated by sonication for 5 min on ice. After centrifugation at 800g for 2 min, a nuclear, mitochondrial, and undigested cellular pellet was isolated. The supernatant was collected and labeled as supernatant 1. The pellet was resuspended in lysis buffer containing 20% glycerol and 0.05% Triton X-100 and sonicated for 5 min on ice. After another round of centrifugation, the supernatant was collected and added to supernatant 1. Supernatant 1 was centrifuged at 100,000g for 30 min at 4°C, producing a pellet (designated as the total cellular membrane fraction) and a supernatant (designated as the cytosolic fraction).
Immunoblot Analysis of PKC and TRPV1 (Total and Phosphorylated)
Immunoblot analysis was carried out on whole DRG cell lysates as well as cytosolic and membrane fractions as described previously in cardiomyocytes with slight modifications. 17 Protein concentration was assessed using the Bradford method. 19 All samples were adjusted to a protein concentration of 1-2 mg/ml in sample buffer, boiled for 5 min, and then kept at Ϫ20°C until use. Equal amounts of protein (50 g) from each fraction were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 12% polyacrylamide gels and transferred to nitrocellulose membranes. Nonspecific binding was blocked with Tris-buffered saline solution (0.1% [v/v] Tween 20 in 20 mM Tris base, 137 mM NaCl adjusted to pH 7.6 with HCl), containing 3% (w/v) bovine serum albumin for 1 h at room temperature. Monoclonal antibodies against total PKC and polyclonal antibodies against S729-phosphorylated PKC (PKCpS 729 ), total TRPV1, and S800-phosphorylated TRPV1 (TRPV1pS 800 ) were diluted 1:1,000 in Trisbuffered saline containing 1% bovine serum albumin for immunoblotting (2 h). After washing three times for 10 min each in Tris-buffered saline, membranes were incubated for 1 h at room temperature with horseradish-peroxidase-linked secondary antibody (goat antimouse and goat antirabbit; 1:5,000 dilution in Tris-buffered saline containing 1% bovine serum albumin). Membranes were again washed, and bound antibody was detected by enhanced chemiluminescence. Immunoreactivity was quantified by scanning densitometry and analyzed using ImageJ software (National Institutes of Health, Washington, DC).
Immunocytochemistry of TRPV1
Mouse DRG neurons were cultured for 2 days on glass coverslips before fixation in 4% formaldehyde for 25 min. Fixed cells were blocked and permeabilized in phosphate-buffered saline containing 3% normal goat serum and 0.3% Triton X-100 and were incubated overnight at 4°C with anti-TRPV1 polyclonal antibody. Nonspecific binding was blocked using 5% milk in a phosphate-buffered saline solution for 1 h at room temperature. Coverslips were washed four times (at 5, 10, 10, and 10 min, respectively) with phosphate-buffered saline before being placed into a light-insulated container. Fluorescein-5-isothiocyanate (1:200) secondary antibody was incubated for 1 h at room temperature. After washing as described above, the coverslips were placed on slides with an 80% Vectashield (Vector Laboratories, Burlingame, CA) solution. Images were acquired using a laserscanning spectral confocal microscope (TCS AOBS SP2; Leica, Heidelberg, Germany) with a 40ϫ oil immersion objective (numerical aperture ϭ 1.4) at zoom 2. An Argon laser was used to excite fluorescein-5-isothiocyanate-labeled TRPV1 at 488 nm. For background removal, a photomultiplier tube offset value was chosen and kept constant, eliminating any issues of image variability. Emission was collected between 500 and 550 nm for fluorescein-5-isothiocyanate.
Statistical Analysis
All experimental protocols were repeated in a minimum of five DRG neurons obtained from at least five different mice. Results obtained from each animal were averaged so that all animals were weighted equally. Within-group comparisons were made using repeated measures one-way analysis of variance and the Bonferroni post hoc test. Comparisons between groups were made using two-way analysis of variance. Differences were considered statistically significant at P Ͻ 0.05. All results are expressed as mean Ϯ SD. Statistical analysis was conducted using NCSS software (Kaysville, UT).
Experimental Protocols
DRG neurons were chosen for study by distinguishing small (less than 30 m) nociceptive neurons (capsaicin-sensitive) from large (more than 40 m) mechanosensitive neurons (capsaicin-insensitive) using a precalibrated eyepiece reticle to measure the diameter of the neuronal cell body. The Diprivan lipid emulsion form of propofol (56 mM [10 mg/ ml] propofol, 10% soybean oil, 2.25% glycerol, 1.2% purified phospholipid) was used in all protocols and will be referred to as propofol throughout the article. Intralipid vehicle (Baxter, Deerfield, IL) was used as a control. The effect of Intralipid was examined at amounts equivalent to those used for the propofol-Intralipid mixture (Diprivan).
Protocol 1: Effect of Propofol on Restoration of TRPV1 Sensitivity in Mouse DRG Neurons.
To determine the extent to which propofol is capable of resensitizing TRPV1 receptors, [Ca 2ϩ ] i was monitored in DRG neurons that were repeatedly exposed to capsaicin (100 nM) every 30 s to induce desensitization of the channel. After desensitization, neurons were subsequently exposed to propofol (1, 5, and 10 M; 10 min) or intralipid (10 M; 10 min) vehicle before restimulation of TRPV1 receptors with capsaicin. Summarized results are expressed as a percentage of the response to the final application of capsaicin in the untreated control.
Protocol 2: Effect of PKC Inhibition on Propofol-induced Restoration of TRPV1 Sensitivity in Mouse DRG Neurons.
To determine the extent to which PKC is involved in the propofol-induced resensitization of TRPV1 receptors, DRG neurons were repeatedly exposed to capsaicin as described in protocol 1. After desensitization, neurons were pretreated with V1-2 (0.5 M) and then exposed to propofol (10 M) in the continued presence of V1-2. Parallel experiments demonstrating the effect of RACK (0.5 M) on resensitization of TRPV1 receptors in the absence of propofol were also performed. Summarized results are expressed as a percentage of the response to the final application of capsaicin in the untreated control.
Protocol 3: Effect of Propofol on Restoration of TRPV1 Sensitivity in DRG Neurons Isolated from PKC-null Mice.
To support our pharmacological findings of a role for PKC in the propofol-induced resensitization of TRPV1 (protocols 1 and 2), protocol 1 was repeated in PKC-null mice using 10 M propofol. Summarized results are expressed as a percentage of the final application of capsaicin in the presence of propofol in DRG neurons from WT mice (control).
Protocol 4: Effect of Propofol on Agonist-induced Desensitization of TRPV1 in Mouse DRG Neurons.
To determine the extent to which propofol may alter agonist-induced desensitization of TRPV1, [Ca 2ϩ ] i was monitored in DRG neurons that were repeatedly exposed to capsaicin (100 nM) every 30 s to induce desensitization of the channel. After desensitization, neurons were subsequently exposed to propofol (1, 5, and 10 M; 30 min) or Intralipid (10 M; 30 min), and DRG neurons were again repeatedly exposed to capsaicin every 30 s. The percentage reduction in the capsaicin response (desensitization) in untreated DRG neurons was compared with the capsaicin response obtained in propofol-treated DRG neurons.
Protocol 5: Effect of Propofol on Agonist-induced TRPV1 Desensitization in DRG Neurons Isolated from PKC-null Mice.
To determine the extent to which PKC is involved in the propofol-induced attenuation of agonist-induced desensitization of TRPV1 receptors, Protocol 4 was repeated in PKC-null mice using 10 M propofol. The percentage reduction in the capsaicin response in propofol-treated DRG neurons from WT mice was compared with the capsaicin response obtained in propofol-treated DRG neurons from PKC-null mice.
Protocol 6: Effect of Propofol on Agonist-induced Painassociated Behaviors in Mice.
To further characterize the extent to which propofol may alter TRPV1 sensitivity, painassociated behaviors in response to topical application of capsaicin were assessed in WT mice. Specifically, capsaicin (500 M, 20 l) was applied to the nasal epithelium, and the duration of pain-associated behaviors was assessed. After the initial exposure to capsaicin, mice were treated with and without propofol (50% in mineral oil) for 10 min, and the duration of pain-associated behaviors was assessed. Capsaicin (500 M, 20 l) was then reapplied, and the duration of pain-associated behavior was reassessed. Protocol 7: Effect of Propofol on PKC Phosphorylation at S729 in Mouse DRG Neurons. To determine the extent to which propofol stimulates the phosphorylation of PKC at S729, a key mechanism in PKC activation, immunoblot analysis of S729 phosphorylated PKC (PKCpS 729 ) in DRG neuronal whole cell fractions was performed before and after treat-ment with propofol (10 M; 10 min) in the presence or absence of V1-2 (0.5 M). Parallel experiments demonstrating the effect of RACK (0.5 M) and Intralipid vehicle (10 M) on PKC S729 phosphorylation were also performed. PKCpS 729 levels were normalized to total PKC protein levels detected in the DRG lysates. Summarized results are expressed as a percentage of the untreated control. To determine the extent to which propofol stimulates phosphorylation of TRPV1 at S800 in DRG neurons, protocol 2 was repeated in WT and PKC-null DRG neurons, and then immunoblot analysis of S800 phosphorylated TRPV1 (TRPV1pS 800 ) was performed. In addition, TRPV1pS 800 levels in the presence of propofol were also measured in parallel using DRG neurons isolated from PKC-null mice. TRPV1pS 800 levels are normalized to total TRPV1 protein levels detected in the lysate. Summarized results are expressed as arbitrary units.
Materials
Anti-PKC and anti-PKCpS 729 antibodies were purchased from Cell Signaling Technology (Danvers, MA). Anti-TRPV1pS 800 antibody was kindly provided by Makoto Tominaga, Ph.D. (National Institute of Natural Sciences, Okazaki, Japan 
Results
Effect of Propofol on Restoration of TRPV1 Sensitivity in Mouse DRG Neurons
Repetitive stimulation of DRG neurons with capsaicin resulted in a progressive decrease (desensitization) in peak [Ca 2ϩ ] i that was maintained after a 10-min pause in capsaicin stimulation as indicated by the lack of any response to capsaicin after reapplication of capsaicin to the bath ( fig. 1A) . In contrast, when propofol (10 M) was added to the bath during the 10-min pause in stimulation, subsequent reapplication of capsaicin resulted in a robust transient increase in [Ca 2ϩ ] i (resensitization) ( fig. 1B ). Intralipid vehicle alone (amount equivalent to that added with 10 M propofol) was unable to restore TRPV1 sensitivity to capsaicin (98.3 Ϯ 7% of control). figure 1E .
Effect of PKC Inhibition on Propofol-induced Restoration of TRPV1 Sensitivity in Mouse DRG Neurons
Effect of Propofol on Restoration of TRPV1 Sensitivity in DRG Neurons Isolated from PKC-null Mice
In DRG neurons obtained from PKC-null mice, the propofol (10 M) failed to restore TRPV1 sensitivity to capsaicin ( fig.  2A ). Summarized data depicting the effect of propofol (10 M) 
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on TRPV1 resensitization in DRG neurons obtained from WT and PKC-null mice are depicted in figure 2B .
Effect of Propofol on Agonist-induced Desensitization of TRPV1 in Mouse DRG Neurons
After successive applications of capsaicin to induce TRPV1 desensitization, a 30-min pause in capsaicin stimulation was able to restore TRPV1 responsiveness to capsaicin as indicated by the robust transient increase in [Ca 2ϩ ] i upon reapplication of capsaicin ( fig. 3A ). Subsequent successive reapplications of capsaicin resulted in a progressive decrease (desensitization) in peak [Ca 2ϩ ] I (fig. 3A) . In contrast, when propofol (10 M) was added to the bath during the 30-min pause in stimulation, successive applications of capsaicin did not result in desensitization in peak [Ca 2ϩ ] i (fig. 3B ). Moreover, when Intralipid (amount of Intralipid equivalent to that added with 10 M propofol) was added to the bath during the 30-min pause in stimulation, successive applications of capsaicin resulted in desensitization in peak [Ca 2ϩ ] i (92.3 Ϯ 3% reduction). Summarized data depicting the effect of propofol (1, 5, and 10 M) on capsaicin-induced desensitization of TRPV1 receptors are depicted in figure 3C .
Effect of Propofol on Agonist-induced Desensitization of TRPV1 in Mouse DRG Neurons Isolated from PKC-null Mice
In DRG neurons obtained from PKC-null mice, successive applications of capsaicin in the presence of propofol resulted in a progressive decrease (desensitization) in peak [Ca 2ϩ ] I (fig. 4A ). Summarized data depicting the effect of propofol (1, 5, and 10 M) on capsaicin-induced desensitization of TRPV1 receptors in DRG neurons obtained from PKCnull mice is depicted in figure 4B .
Effect of Propofol on Agonist-induced Pain-associated Behaviors in Mice
Initial exposure of capsaicin (500 M, 20 l) to the nasal epithelium of untreated control animals resulted in painassociated behaviors that lasted 154 Ϯ 13 s ( fig. 5A ). After the 10-min rest period, the subsequent reapplication of capsaicin resulted in pain-associated behaviors that lasted 98 Ϯ 11 s (36 Ϯ 4% reduction) ( fig. 5A ). However, when propofol was applied during the 10-min rest period and capsaicin was then reapplied, the duration of pain-associated behaviors was 219 Ϯ 19 s compared with 142 Ϯ 14 s for the initial application of capsaicin (54.4 Ϯ 10.5% increase) ( fig. 5A ). In addition, application of propofol during the rest period resulted in pain-associated behaviors lasting 147 Ϯ 21 s. Summarized data depicting the effect of propofol on agonistinduced pain-associated behaviors is depicted in figure 5B . figure 6B .
Effect of Propofol on PKC Phosphorylation at S729 in Mouse DRG Neurons
Effect of Propofol on PKC Translocation from Cytosolic to Membrane Fractions in Mouse DRG Neurons
Immunoblot analysis revealed that PKC was primarily associated with the cytosolic fraction but had some association with the membrane fraction in untreated DRG neurons ( fig. 6C ). After treatment with propofol (10 M), the amount of immunodetectable PKC in the membrane fraction was increased ( fig. 6C ). Pretreatment with V1-2 (0.5 M) attenuated the propofol-induced increase of PKC in the membrane fraction, whereas treatment with RACK (0.5 M) stimulated translocation of PKC from cytosolic to membrane fraction ( fig. 6C ). Intralipid vehicle did not have any effect on the membrane association of PKC (99 Ϯ 4% of control). Summarized data depicting the relative association of PKC with the cytosolic and membrane fractions, before and after treatment with propofol alone, propofol in the presence of V1-2, RACK alone, or Intralipid alone are depicted in figure 6D .
Effect of Propofol on PKC Intracellular Localization in Mouse DRG Neurons
Immunocytochemical analysis revealed a diffuse deposition of PKC in the cytoplasm of untreated control DRG neurons ( fig. 7A ). Propofol (10 M) stimulated a greater association of PKC to the periphery of the DRG neurons ( fig. 7B ). The propofol-induced peripheral association of PKC was inhibited by V1-2 (0.5 M) ( fig. 7C ) and mimicked by RACK (0.5 M) ( fig. 7D ). Intralipid vehicle had no effect on PKC intracellular localization.
Effect of Propofol on TRPV1 Phosphorylation at S800 in Mouse DRG Neurons
Immunoblot analysis revealed that there was no detectable TRPV1pS 800 in untreated DRG neurons obtained from WT mice. In the presence of propofol (10 M), TRPV1pS 800 levels were increased in WT DRG neurons but remained unchanged in DRG neurons isolated from PKC-null mice ( fig. 8A) . RACK also increased TRPV1pS 800 levels, whereas Intralipid had no effect on TRPV1 phosphorylation at S800 ( fig. 8A ). Summarized data depicting the effect of propofol (10 M) alone, RACK (0.5 M) alone, and Intralipid alone on TRPV1pS 800 levels in WT mouse DRG neurons as well as the effect of propofol alone on TRPV1pS 800 levels in DRG neurons obtained from PKCnull mice are depicted in figure 8B .
Discussion
This is the first study to assess the extent to which propofol is capable of modulating TRPV1 receptor sensitivity in nociceptive DRG sensory neurons. Recent studies have indicated that propofol does not activate TRPV1 in DRG neurons 14 or in human embryonic kidney 293 cells transiently expressing the TRPV1 receptor. 20 However, the extent to which propofol is capable of restoring TRPV1 sensitivity to agonist activation after agonist desensitization or modulating agonistinduced desensitization of TRPV1 was not assessed in these or any other studies. On the other hand, recent studies have demonstrated that PKC can phosphorylate TRPV1 receptors at S800, restoring TRPV1 sensitivity to agonist stimulation. 5, 13 Moreover, our lab has previously shown that propofol can activate and allosterically modulate recombinant PKC as well activate PKC in freshly isolated adult rat ventricular cardiomyocytes. 17, 18, 21, 22 As a result, we tested the hypothesis that propofol can restore TRPV1 receptor sensitivity (resensitizes) of desensitized TRPV1 receptors via a PKC-dependent pathway. We also tested the hypothesis that propofol attenuates agonist-induced desensitization of TRPV1 via a PKC-dependent pathway. In addition, we tested the hypothesis that propofol prolongs agonist-induced pain-associated behaviors in mice. Our key finding is that the supraclinical concentration of propofol (10 M) restores the sensitivity of TRPV1 receptors to capsaicin activation via a PKC-dependent mechanism that is associated with an increase in phosphorylation of TRPV1 at S800 in mouse DRG neurons. In addition, propofol (10 M) attenuates agonistinduced desensitization of TRPV1 in a PKC-dependent manner and prolongs agonist-induced pain-associated behaviors. Moreover, propofol (10 M) stimulates the phosphorylation of PKC at S729 and induces the translocation of PKC from cytosolic to membrane fractions, indicating PKC activation
Effect of Propofol on Restoration of TRPV1 Sensitivity in Mouse DRG Neurons
PKC has been shown to restore TRPV1 sensitivity to capsaicin through rephosphorylation of the channel at S800. 5, 13 In addition, a recent study from our laboratory indicated that propofol stimulates translocation of several PKC isoforms, including PKC, to distinct intracellular locations in cardiomyocytes. 17 Therefore, to examine whether propofol is capable of restoring TRPV1 receptor sensitivity to agonist stimulation, we treated DRG neurons with propofol after desensitization with capsaicin and then measured [Ca 2ϩ ] i in response to another challenge with capsaicin. Our data indicate that after capsaicin-induced TRPV1 desensitization, addition of propofol itself resulted in no increase in [Ca 2ϩ ] i . However, continued exposure of DRG neurons to propofol (10 M) and reapplication of capsaicin restored TRPV1 sensitivity, resulting in a transient rise in [Ca 2ϩ ] i . The restoration of TRPV1 sensitivity is not likely to be due to timedependent recovery from desensitization, because incubation of DRG neurons in control buffer for an equivalent period of time did not restore TRPV1 sensitivity, as evidenced by the lack of any increase in [Ca 2ϩ ] i . In addition, the Intralipid emulsion did not restore TRPV1, indicating that "pure" propofol (2,6 diisopropyl phenol), and not the lipid emulsion, can restore TRPV1 sensitivity.
Effect of PKC Inhibition on Propofol-induced Restoration of TRPV1 Sensitivity in Mouse DRG Neurons
Although capsaicin acutely activates TRPV1 receptors in sensory neurons eliciting a painful response, repeated stimulation with capsaicin causes TRPV1 receptors to undergo desensitization, leading to a decrease in receptor activation. 10, 23 The process of receptor desensitization and resensitization is important for mediating TRPV1 receptor signal transduction in DRG neurons. 5 Although the mechanisms of desensitization are not entirely clear, resensitization of the TRPV1 receptor seems to involve activation of a PKC-dependent pathway. 5, 12 Specifically, PKC has been shown to reverse TRPV1 desensitization by capsaicin through rephosphorylation of the channel at S800. 5, 13 To examine whether propofol exerts a resensitizing effect on TRPV1 receptors via PKC, we treated DRG neurons with propofol in the presence or absence of V1-2 after desensitization and subsequently measured [Ca 2ϩ ] i in response to another challenge with capsaicin. Our findings indicate that the propofol-induced resensitization of TRPV1 is almost fully attenuated in DRG neurons treated with V1-2 and mimicked by RACK. These results indicate that PKC is needed for propofol to resensitize TRPV1. To further substantiate these results, we next assessed the effect of propofol on TRPV1 resensitization in DRG neurons isolated from PKC-null mice. In PKC-null mice, propofol was not able to restore TRPV1 sensitivity to capsaicin, further indicating that PKC activation is critical for restoring the sensitivity of desensitized TRPV1. Moreover, the finding that the propofol-induced resensitization of TRPV1 was almost fully attenuated in PKC-null mice indicates that other isoforms of PKC are most likely not involved. 
Effect of Propofol on Agonist-induced Desensitization of TRPV1 in Mouse DRG Neurons
The mechanisms governing desensitization of TRPV1 are complex but involve calcium-dependent and -independent mechanisms. 24 For instance, capsaicin-induced TRPV1 desensitization is mediated by calcineurin-dependent dephosphorylation of the receptor but is mitigated by PKC-dependent phosphorylation. 24 Although our findings indicate that propofol can restore the sensitivity of TRPV1 that has been previously desensitized by capsaicin, we next wanted to determine whether propofol could modulate the ability of capsaicin to desensitize TRPV1 via a PKC-dependent pathway.
Our findings indicate that capsaicin-induced desensitization of TRPV1 is reduced in the presence of propofol, as indicated by the increased number of applications of capsaicin that are required to fully desensitize the receptor. Moreover, propofol also prolonged the decay of [Ca 2ϩ ] i in both WT and PKC-null mice, consistent with our previous finding that propofol prolongs the decay of [Ca 2ϩ ] i during the restoration of TRPV1 sensitivity as previously mentioned. Although other agonists of TRPV1 (protons and heat) were not tested in these experiments, our findings point to a potential role of propofol in limiting the ability of the TRPV1 receptor to become desensitized, a property that may alter other signaling pathways regulating pain, including other members of the transient receptor potential family of receptors. For instance, the propofol-induced regulation of TRPV1 function may also affect TRPA1 receptor function due to the known interactions of the two receptors. 16 
Effect of Propofol on Agonist-induced Desensitization of TRPV1 in Mouse DRG Neurons Isolated from PKC-null Mice
PKC has been shown to regulate desensitization of TRPV1 by capsaicin. 25 Based on our findings that propofol can restore the sensitivity of previously desensitized TRPV1 receptors, we wanted to determine whether or not propofol attenuates the ability of TRPV1 to become desensitized via activation of PKC. Our findings indicate that PKC is required, at least in part, for propofol to inhibit TRPV1 to desensitization by repeated agonist stimulation. Elucidation of the mechanisms by which propofol alters TRPV1 function will provide better mechanistic insight into how propofol may regulate other pain receptors.
Effect of Propofol on Agonist-induced Pain-associated Behaviors in Mice
To further characterize the extent to which propofol modifies TRPV1 sensitivity, the effect of propofol on pain-associated behaviors was assessed in WT mice. We assessed the effect of propofol on the duration of nose-wiping in and out of bedding in response to a topical application of capsaicin to the nasal epithelium. This allowed us to assess the effects of locally administered propofol without the potential confounding depressive effects of propofol on the central nervous system. Using this model, we determined that capsaicin induced a pain-associated behavior in mice, and that a sub-sequent second application of capsaicin (after a 10-min rest period) resulted in a marked reduction in the duration of the nocifensive behavior, indicating reduced TRPV1 sensitivity. In contrast, application of propofol during the 10-min rest period increased the duration of pain-associated behaviors induced by the second application of capsaicin, indicating an increase in TRPV1 sensitivity. These data provide compelling evidence further supporting our in vitro data of a propofol-induced restoration of TRPV1 sensitivity, as well as a propofol-induced attenuation of agonist-induced TRPV1 desensitization.
Effect of Propofol on PKC Phosphorylation at S729 in Mouse DRG Neurons
To provide biochemical evidence to further support our finding of a propofol-induced restoration of TRPV1 sensitivity via PKC, we next assessed the effect of propofol on PKC activation. Activation of PKC, as well as membrane targeting and substrate specificity, is regulated by several factors, including phosphorylation, diacylglycerol, phospholipids, and anchoring proteins. As part of the activation process, PKC is auto-phosphorylated at S729 in the hydrophobic motif of the enzyme, rendering it catalytically competent. Our findings indicate that propofol increases PKCpS 729 levels in DRG neurons. These results are consistent with our previous finding that propofol can increase the S729 phosphorylation of recombinant PKC. 18 Moreover, Intralipid was also capable of stimulating S729 phosphorylation of PKC. This is probably due to the presence of fatty acids (soy bean oil) and phospholipids (lecithin), which create the lipid emulsion facilitating solubility of propofol. Fatty acids are known to activate some isoforms of PKC, and phospholipids serve as cofactors for activation. 26 However, the Intralipidinduced phosphorylation of PKC is somewhat surprising, because Intralipid did not resensitize TRPV1. This may be because S729 phosphorylation of PKC only renders the enzyme catalytically competent. Other events subsequent to S729 phosphorylation such as pseudosubstrate displacement must occur for full PKC activation.
Effect of Propofol on PKC Translocation from Cytosolic to Membrane Fractions in Mouse DRG Neurons
A subcellular translocation of PKC isoforms from the cytosolic to membrane fraction is associated with activation of PKC isoforms, and translocation is facilitated by receptors for activated C kinases located in cellular membranes. 27, 28 Binding of the PKC isoform to its specific receptors for activated C kinase is also critical to the phosphorylation of substrate proteins that are specific for that PKC isoform. This study is the first to examine the translocation of PKC from cytosolic to membrane fractions in DRG neurons after exposure to propofol. Our findings indicate that propofol increases the translocation of PKC from the cytosolic to membrane fraction in DRG neurons. This result is consistent with our previous finding that propofol stimulated the translocation of PKC from cytosolic to membrane fraction in cardiomyocytes. 17 Surprisingly, Intralipid did not induce translocation of PKC. Again, as mentioned earlier, Intralipid may increase S729 phosphorylation of PKC without inducing membrane translocation.
Effect of Propofol on PKC Intracellular Localization in Mouse DRG Neurons
Translocation of PKC from cytosolic to membrane fraction indicates movement of the protein from one intracellular domain to another. Previous studies examining the intracellular localization of individual PKC isoforms before and after an intervention have been useful for identifying the potential cellular target(s) of each isoform. 29, 30 Identifying the cellular targets of PKC provides important information for predicting changes in cellular regulation and function that may occur. Our novel findings indicate that propofol increases the association of PKC at the periphery of DRG neurons. Combined with the finding that propofol induces the translocation of PKC to membrane fractions, this finding suggests that propofol induces the translocation of PKC in DRG neurons to the plasma membrane, potentially interacting with and phosphorylating TRPV1 located in the plasma membrane. As a result, we next examined the extent to which propofol increased the PKC-dependent phosphorylation of TRPV1 at S800.
Effect of Propofol on TRPV1 Phosphorylation at S800 in Mouse DRG Neurons
The PKC-dependent phosphorylation of TRPV1 at S800 has been shown to increase the sensitivity of TRPV1 to agonist stimulation. 5, 13 The propofol-induced activation of PKC and the subsequent phosphorylation of TRPV1 at S800 may be the mechanism by which propofol not only restores the sensitivity of TRPV1 to capsaicin but also attenuates the ability of capsaicin to desensitize TRPV1. Our novel findings indicate that the propofol increased TRPV1pS 800 levels in DRG neurons and that the propofolinduced increase in TRPV1 phosphorylation was completely blocked in DRG neurons isolated from PKC-null mice. These results indicate that the propofol-induced phosphorylation of TRPV1 by PKC may constitute the underlying mechanism by which propofol resensitizes TRPV1 to capsaicin stimulation and attenuates capsaicin-induced TRPV1 desensitization. Further studies incorporating cell lines transfected with mutant forms of TRPV1 in which the PKC-dependent phosphorylation site (S800) has been removed will be needed to convincingly conclude that the propofol-induced phosphorylation of TRPV1 at S800 is the mechanism of the propofol-induced modulation of TRPV1 sensitivity.
The clinical relevance of the current findings regarding the effect of propofol on TRPV1 sensitivity is doubtful for the following reasons. First, propofol had no effect on TRPV1 sensitivity except at 10 M, a propofol concentration outside the clinically relevant range. The peak plasma concentration of propofol after bolus administration has been estimated at 50 M. 31 In normal circumstances, the steady-state free plasma concentration of propofol would probably not exceed 1-2 M, because 97-98% binds to serum protein. 32 Therefore, 10 M propofol is a supraclinical concentration. Second, propofol did not exert a concentration-dependent effect on TRPV1 sensitivity. Both pharmacologists and physiologists recognize the importance of observing concentration-dependent effects of drugs on physiologic function to establish any potential clinical significance of the drug. Unfortunately, we observed no concentration-dependent effect of propofol. This is a confusing issue that remains unresolved, but it may be due to some pharmacological threshold effect of propofol on TRPV1 receptor function. Although the data provide some insight into the potential pharmacological interactions between propofol and TRPV1 receptors, they provide little insight into the clinical relevance of their interaction.
